VIVACTA Biotechnology Overview

  • Year Founded
  • 2025

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A1

  • Investors
  • 11

VIVACTA Biotechnology General Information

Description

Developer of cell therapies intended to treat cancer and autoimmune diseases. The company offers in vivo CAR-T therapies utilizing targeted lipid nanoparticle and mRNA delivery technologies, enabling healthcare providers to administer immune-based treatments with improved accessibility and simplified treatment processes.

Contact Information

Website
www.vivacta-bio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 24, Lane 388, Shengrong Road
  • Pudong New Area
  • Shanghai, 201315
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Nanotechnology, Life Sciences, Oncology
Corporate Office
  • Building 24, Lane 388, Shengrong Road
  • Pudong New Area
  • Shanghai, 201315
  • China
+86 021

VIVACTA Biotechnology Timeline

2026
Date FoundedFinancing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

VIVACTA Biotechnology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A1) 13-Apr-2026 Completed Generating Revenue
3. Early Stage VC (Series A) 26-Jan-2026 Completed Generating Revenue
2. Seed Round 10-Oct-2025 $14M $14M Completed Startup
1. Spin-Off 25-Jun-2025 Completed Startup
To view VIVACTA Biotechnology’s complete valuation and funding history, request access »

VIVACTA Biotechnology Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Decheng Capital Venture Capital Minority
Eisai Innovation Corporate Venture Capital Minority
OrbiMed Growth/Expansion Minority
C&D Emerging Industry Equity Investment Corporate Venture Capital Minority
Eisai Corporate Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial

VIVACTA Biotechnology FAQs

  • When was VIVACTA Biotechnology founded?

    VIVACTA Biotechnology was founded in 2025.

  • Where is VIVACTA Biotechnology headquartered?

    VIVACTA Biotechnology is headquartered in Shanghai, China.

  • What industry is VIVACTA Biotechnology in?

    VIVACTA Biotechnology’s primary industry is Drug Discovery.

  • Is VIVACTA Biotechnology a private or public company?

    VIVACTA Biotechnology is a Private company.

  • What is VIVACTA Biotechnology’s current revenue?

    The current revenue for VIVACTA Biotechnology is .

  • How much funding has VIVACTA Biotechnology raised over time?

    VIVACTA Biotechnology has raised $45M.

  • Who are VIVACTA Biotechnology’s investors?

    Decheng Capital, Eisai Innovation, OrbiMed, C&D Emerging Industry Equity Investment, and Eisai are 5 of 11 investors who have invested in VIVACTA Biotechnology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process